185 related articles for article (PubMed ID: 16163198)
1. Stem cell transplantation for autoimmune diseases.
Burt RK; Verda L; Statkute L; Quigley K; Yaung K; Brush M; Oyama Y
Clin Adv Hematol Oncol; 2004 May; 2(5):313-9. PubMed ID: 16163198
[TBL] [Abstract][Full Text] [Related]
2. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia.
Tam CS; Khouri I
Hematol Oncol; 2009 Jun; 27(2):53-60. PubMed ID: 19358149
[TBL] [Abstract][Full Text] [Related]
3. Stem cell transplantation for severe autoimmune diseases: progress and problems.
Marmont AM
Haematologica; 1998 Aug; 83(8):733-43. PubMed ID: 9793258
[TBL] [Abstract][Full Text] [Related]
4. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
[No Abstract] [Full Text] [Related]
5. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis.
Burt RK; Patel D; Thomas J; Yeager A; Traynor A; Heipe F; Arnold R; Marmont A; Collier D; Glatstein E; Snowden J
Bone Marrow Transplant; 2004 Nov; 34(9):745-51. PubMed ID: 15361910
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
Oyama Y; Traynor AE; Barr W; Burt RK
Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S81-3. PubMed ID: 12931250
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell transplantation procedures.
Saccardi R; Gualandi F
Autoimmunity; 2008 Dec; 41(8):570-6. PubMed ID: 18958744
[TBL] [Abstract][Full Text] [Related]
8. Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning.
Suslova IM; Theodoropoulos DS; Cullen NA; Tetarnikova MK; Tetarnikov AS; Kolchak NA
Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):785-8. PubMed ID: 21061838
[TBL] [Abstract][Full Text] [Related]
9. [Hematopoietic stem cell transplantation in autoimmune diseases].
Albarracín F; López Meiller MJ; Naswetter G; Longoni H
Medicina (B Aires); 2008; 68(2):153-63. PubMed ID: 18499968
[TBL] [Abstract][Full Text] [Related]
10. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
11. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
[TBL] [Abstract][Full Text] [Related]
12. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
[TBL] [Abstract][Full Text] [Related]
13. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease.
Milanetti F; Abinun M; Voltarelli JC; Burt RK
Pediatr Clin North Am; 2010 Feb; 57(1):239-71. PubMed ID: 20307720
[TBL] [Abstract][Full Text] [Related]
14. Chimerism does not predict for outcome after alemtuzumab based conditioning.
Michaelis L; Lin S; Joseph L; Artz AS; Kline J; Pollyea D; Stock W; Rich E; Collins-Jones D; Casey B; Del Cerro P; van Besien K
Bone Marrow Transplant; 2007 Jul; 40(2):181. PubMed ID: 17502895
[No Abstract] [Full Text] [Related]
15. Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens.
Nash RA
Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S77-80. PubMed ID: 12931249
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for autoimmune diseases: issues in protocol development.
McSweeney PA; Nash RA; Storb R; Furst DE; Gauthier J; Sullivan KM
J Rheumatol Suppl; 1997 May; 48():79-84. PubMed ID: 9150124
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation in the treatment of autoimmune diseases].
Váróczy L; Szegedi G
Orv Hetil; 2000 Mar; 141(12):595-600. PubMed ID: 10769542
[TBL] [Abstract][Full Text] [Related]
18. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases.
Hinterberger W; Hinterberger-Fischer M; Marmont A
Bone Marrow Transplant; 2002 Dec; 30(11):753-9. PubMed ID: 12439698
[TBL] [Abstract][Full Text] [Related]
19. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives.
Névessignsky MT; Ferster A
Nephrol Dial Transplant; 2006 May; 21(5):1154-7. PubMed ID: 16431888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
